Company news
Kala Bio, Inc. news in 2026
Kala Bio, Inc.'s news releases, calls and decks from 2026, newest first.
KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception
September 29, 2026
KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team
September 17, 2026
Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
September 3, 2026
Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
September 1, 2026
KALA BIO Announces Reverse Stock Split
May 7, 2026
Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine
April 21, 2026
Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities
April 1, 2026
KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live
March 30, 2026
Red Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psilocybin Drug Candidate
March 18, 2026
Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate
March 18, 2026
Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates
March 11, 2026
KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency”
March 4, 2026
KALA BIO Settles Approximately $10.6 million of Debt
January 5, 2026